REGULATION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS WITH INSULIN-LIKE-GROWTH-FACTOR (IGF-1) AND IGF-1 IGF-BINDING PROTEIN-3 COMPLEX (IGF-1 IGFBP3)/
Ae. Lovettracke et al., REGULATION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS WITH INSULIN-LIKE-GROWTH-FACTOR (IGF-1) AND IGF-1 IGF-BINDING PROTEIN-3 COMPLEX (IGF-1 IGFBP3)/, The Journal of clinical investigation, 101(8), 1998, pp. 1797-1804
Insulin-like growth factor (IGF)-1 is a cytokine that promotes oligode
ndrocyte development and myelin production. This study investigated wh
ether treatment of chronic, relapsing murine experimental autoimmune e
ncephalomyelitis (EAE) with IGF-1 or IGF-1 associated with its binding
protein, IGFBP3, altered the course of disease. Administration of IGF
-1/IGFBP3 (1-100 mg/kg per day) delayed the onset of disease in a dose
-dependent manner and histologic examination showed a delay in inflamm
atory cells entering the central nervous system. However, once signs o
f EAE developed, disease was enhanced in the mice that had been given
the highest dose of IGF-1/IGFBP3. Treatment with IGF-1/IGFBP3 after th
e onset of signs resulted in a severe relapse. Administration of free
IGF-1 (10 mg/kg per day) provided mild protection when given before di
sease onset, but did not significantly alter the course of disease if
given after disease onset. Possible mechanisms that could explain the
altered disease in IGF-1/IGFBP3-treated mice included (a) IGF-1/IGFBP3
administration delayed the onset of EAE by downregulating ICAM-1 gene
expression in the central nervous system, and (b) IGF-1/IGFBP3 treatm
ent of EAE resulted in more severe disease due to enhanced expansion o
f encephalitogenic T cells. Although IGF-1 may enhance remyelination,
these results indicate that administration of IGF-1 associated with IG
FBP3 may also accentuate autoimmune demyelinating disease.